Compare Ascendis Pharma A/S (ASND) vs Conagra Brands Inc (CAG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Conagra Brands Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Conagra Brands Inc trades at $13.85 (market cap $6.62B). The key difference: Ascendis Pharma A/S is far larger — about 2.7× Conagra Brands Inc's market cap, and Conagra Brands Inc pays a 10.12% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CAG | |
|---|---|---|
Market Cap | $17.74B | $6.62B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $20.02 |
52-Week Low | $163.32 | $12.58 |
Enterprise Value | $18.11B | $13.89B |
Dividend Yield | — | 10.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Conagra Brands (CAG) trades at $13.83, up 3.52% today but remains near its 52-week lows with a bearish technical outlook. The stock shows mixed fundamentals with a negative net income margin of -0.39% despite recent revenue stabilization around $11.6B. Analyst sentiment is cautious with 62.5% hold ratings, while recent news highlights concerns about dividend sustainability given the company's 10%+ yield and elevated debt levels.
CAG presents a high-risk opportunity with its deeply discounted valuation (P/E 10.06, P/B 0.81) and substantial dividend yield, but faces significant headwinds including declining earnings, high leverage, and competitive pressures in the consumer staples sector. The upcoming Q2 2026 earnings report on July 15 will be critical for confirming operational turnaround prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →
